Catalyst Pharmaceutical Partners, Inc. CPRX today announced that researchers at the University of Pennsylvania have commenced a 60 subject, double-blind, placebo-controlled, investigator-sponsored study to evaluate the use of CPP-109 (vigabatrin) for the treatment of patients addicted to both cocaine and alcohol.
The researchers hope that the results from their study of CPP-109 will support the conduct of a larger clinical trial that could support FDA approval of CPP-109 as a treatment for cocaine and alcohol co-dependency. Such results, if successful, would also expand upon the initial promising results reported by Brodie, et al. in November 2009 in the American Journal of Psychiatry, in which significantly increased abstinence from alcohol use in subjects taking vigabatrin was also reported.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in